key: cord-0815322-qtjsrb1n authors: Nazli Zeka, Arzu; Avkan‐Oguz, Vildan; Irmak, Caglar; Eren Kutsoylu, Oya; Alp Cavus, Sema; Kuruüzüm, Ziya; Ergon, M. Cem title: Daily inpatient ertapenem therapy can be an alternative to hospitalization for the treatment of complicated urinary tract infections during the COVID‐19 pandemic date: 2021-04-20 journal: Int J Clin Pract DOI: 10.1111/ijcp.14230 sha: d3e0a63b24509ad38825e1729227c3480f329f99 doc_id: 815322 cord_uid: qtjsrb1n BACKGROUND: Physicians hospitalize the patients with complicated urinary tract infections (cUTIs) when they need intravenous antibiotics and outpatient parenteral antimicrobial therapy (OPAT) is unavailable. Daily inpatient antimicrobial therapy is an alternative to hospitalization, which is similar to OPAT; patients go home after they are administered antibiotics in a separate room in the hospital setting. OBJECTIVES: We assessed our previous daily inpatient practice to revitalize the model in the COVID‐19 era. MATERIALS AND METHODS: We retrospectively evaluated the clinical and microbiological responses and the cost effectiveness of the patients with cUTIs who received daily inpatient ertapenem therapy. RESULTS: Our study population was 136 patients in 156 episodes. It was a difficult‐to‐treat group with older age (mean 63.0 ± 14.8 years) and a high burden of underlying conditions (86.5%). The most common causative organisms were Escherichia coli (74.4%) and Klebsiella pneumoniae (19.2%); 89.7% of the isolates were producing extended‐spectrum beta lactamase (ESBL). The microbiologic and clinical success rates were 82.1% and 95.5%, respectively. The patients required hospitalization in 16 episodes (10.2%) because of clinical failures (3.8%), superinfections (2%), planned invasive interventions (3.2%), and side effects (1.2%). Our university hospital saved 1608 bed‐days and 2596 € (9702 TL) bed costs. CONCLUSIONS: In the COVID‐19 pandemic period, this seems to be an effective, safe, and cost‐effective way to decrease hospitalizations for cUTIs in settings where OPAT is unavailable. In the COVID-19 period, reducing hospitalization became important to prevent the spread of SARS-COV-2 infection. In Turkey, physicians hospitalize the patients with urinary tract infections (UTIs) who require intravenous (IV) antibiotic treatment because the Outpatient Parenteral Antibiotic Treatment (OPAT) for UTI is not reimbursed. Extended-spectrum beta lactamase (ESBL)-producing urinary pathogens are steadily increasing in Turkey, 1-6 which usually require IV carbapenems because oral antibiotic options are limited. However, this increases the hospitalization rate, related costs, 7 and the risk of hospital-acquired infections including SARS-CoV-2. 8 Daily antimicrobial therapy is the administration of IV antibiotics in the context of daily inpatient service. We practiced it in our hospital between 2014 and 2018 until it was interrupted due to the reconstruction procedures in the clinic. After the COVID-19 pandemic, we revitalized the idea for patients who do not require hospitalization but need treatment with parenteral antibiotics. Ertapenem is a carbapenem with once-daily dosing for ESBL positive pathogens, 9 that is reimbursed for daily inpatient services and chosen by the majority of physicians for the treatment of UTIs requiring IV antibiotics. We aimed to assess patients with complicated UTI (cUTI) who received daily inpatient ertapenem therapy with a new perspective to create a model to reduce hospitalizations in the COVID-19 era. To our knowledge, this is the first paper on this practice from countries where OPAT is unavailable. Our study protocol received "Dokuz Eylül University Non-invasive Studies Ethical Committee" approval (06.03.219; 2019/05-22). We included patients aged18 years and above with a diagnosis of cUTI who received daily inpatient ertapenem treatment. We excluded patients without urine culture, who received ertapenem for less than 3 days, who used ertapenem for other diagnoses and those who were treated with other antibiotics. We defined cUTI as UTI that developed in functionally, metabolically, or anatomically abnormal hosts or that was caused by multidrug-resistant pathogens (MDR) as described previously. 10 We noted comorbidities, anatomical, and functional abnormalities of the urinary tract, clinical failures, hospitalization needs, and adverse events retrospectively from medical records of the hospital. OPAT is very limited in the reimbursement system of Turkey (only teicoplanin for chronic osteomyelitis and ceftriaxone 2gr for the first dose of acute meningitis prior to the transfer of the patient). Thus, physicians have to hospitalize patients with UTIs when they cannot treat it with oral or intramuscular antibiotics (upper UTIs, recurrent lower UTIs, and UTIs caused by resistant bacteria). The patients were admitted to the hospital every day with antibiotics being provided from the hospital pharmacy. After the administration of IV ertapenem by a nurse in a separate room in a distant building, they were discharged. The advantages are that patients stay in the hospital for less than 30 minutes; they do not occupy hospital beds and have a lower risk for developing hospital-acquired infections. The disadvantages are that patients have to travel to and from and go through a check-in process at the hospital every day. • Daily inpatient ertapenem therapy can be a model for these countries, especially in COVID-19 era. by the Clinical and Laboratory Standards Institute (CLSI), Wayne, PA, USA. 11 ESBL production of the isolates was investigated by the combination disc test using discs containing cefotaxime and ceftazidime as mono drugs and in combination with clavulanic acid. 11 We assessed urine cultures before treatment, at 48-72 hours of We used IBM SPSS 23.0 program for statistical analysis. Skewness, kurtosis, and Kolmogorov-Smirnov (K-S) test were used for the assessment of normality. Continuous variables were compared with the Mann-Whitney U test because of the abnormal distribution of our data. Chi-square test was used for categorical variables. We accepted the probability of type 1 error as ɑ = 0.05 in all tests. A P < .05 was considered significant. Total costs for all patients and hospital bed costs for hospitalized patients were calculated based on the records of the hospital fiscal office. All costs were calculated in Turkish liras (TL) and were converted to Euros (€) according to the exchange rates of the Turkey Central Bank between 2014 and 2018. 12 The public transportation fees were not included in the actual costs because of the high variety of distance. In our hospital, 289 episodes of daily inpatient antimicrobial therapy were administered between January 1, 2014 and September 1, (Table 1) . Thirty-six patients (%23) had one urologic catheter (double j stent, nephrostomy, urostomy, cystostomy), six patients (%3.8) had two, and one patient (%0.6) had three of them. The reasons of invasive urologic catheters, 17 (%47) bladder cancer, 10 (%27.7) nephrolithiasis, 4 (%11.1) ureteral stenosis, 2 (%5.5) ureter injury during operation, 1 (% 2.7) cervix cancer, 1 (%2.7) renal cancer, and 1 (%2.7) neurogenic bladder. The man duration of catheters was 7.8 month (1-96 month). One-third of the patients had a history of hospitalization due to UTIs in the last 6 months. Most of the patients had received previous oral antibiotic treatment ( Table 1 ). The most common oral antibiotics were fosfomycin (63, 40.4%) and third-generation cephalosporin (54; 34.6%) followed by quinolones (45; 28.8%). The remaining were nitrofurantoin (37; 23.7%), second-generation cephalosporin (37; 23.7%), amoxicillin/clavulanic acid (34; 21.8%), and trimethoprimsulfamethoxazole (18; 11.5%). The first control cultures (48-72 hours) were available in 140 (89.7%) episodes ( Physicians referred patients to daily inpatient antibiotic therapy either from the outpatient clinic to receive a full course of antibiotics or from inpatient services to complete an already initiated antibiotic course. In 46.8% of the episodes, patients completed a full course of antibiotic therapy as only daily inpatient therapy. The mean duration of the episodes was 10 days (1-28). Sixteen patients had more than one episode ( Ertapenem is a common choice of antibiotic for ESBL-producing bacteria. 13, 14, 18, 19 It is licensed in Turkey for various indications including complicated UTIs. 20 Once a day dosing of the antibiotic makes it convenient for OPAT. 21 The use of ertapenem for OPAT was reported earlier in cUTIs with microbiologic eradication rates between 54.1% and 90% and with higher rates (92% and 96%) of clinical success. [22] [23] [24] [25] [26] OPAT for UTIs is a practical way of treating patients who do not need hospitalization but require IV antibiotic treatment. 22, 27 OPAT was reported as safe and cost-effective 24, 26 and more preferable for healthcare professionals and for patients than inpatient care. 28 However, the health system in Turkey does not allow the use of OPAT for the treatment of UTIs. While this study provides real-life data for daily inpatient therapy as an alternative to hospitalization, which may serve as a model for centers to decrease hospitalization rates in the treatment of cUTIs, its single center retrospective design, and the lack of molecular analysis, which prevents comparison of bacteria isolated at baseline with those recovered from control cultures are its major limitations. Our study shows that daily inpatient therapy in UTIs with ertapenem is effective with a high success rate, acceptable with a high adherence rate, and safe with very few adverse events. It can reduce the hospitalization rates significantly and might have a positive effect in reducing COVID-19 transmission at the hospital. The authors declare no conflict of interest. Arzu Nazli Zeka https://orcid.org/0000-0001-8859-6432 Epidemiology and susceptibility of pathogens from SMART 2011-12 Turkey: evaluation of hospitalacquired versus community-acquired urinary tract infections and ICU-versus non-ICU-associated intra-abdominal infections Extendedspectrum beta-lactamase production by enterobacteriaceae isolates from urine cultures of outpatients: results of a 7-year follow-up Antibiotic resistance patterns of escherichia coli strains isolated from urine cultures in turkey: a meta-analysis Investigation of risk factors for community-acquired urinary tract infections caused by extended-spectrum beta-lactamase Escherichia coli and Klebsiella species Turkish nosocomial urinary tract infection study group. hospital-acquired urinary tract infection point prevalence in Turkey: differences in risk factors among patient groups The emerging resistance in nosocomial urinary tract infections: from the pediatrics perspective Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China Cost analysis of ertapenem therapy for urinary tract ınfections and assessment of its suitability for outpatient parenteral antibiotic therapy programme in Turkey Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections Complicated urinary tract infections Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty second informational supplement update. CLSI document M100-S22 U Turkey foreign currency exchange rates archive Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extendedspectrum β-lactamase producing gram-negative bacteria Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum betalactamase-producing Escherichia coli-related complicated lower urinary tract infection Nitrofurantoin in the treatment of extended-spectrum β-lactamaseproducing Escherichia coli-related lower urinary tract infection Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extendedspectrum β-lactamase-producing Escherichia coli in children Treatment efficacy and superinfection rates in complicated urinary tract infections treated with ertapenem or piperacillin tazobactam The clinical efficacy and safety of ertapenem for the treatment of complicated urinary tract infections caused by ESBL-producing bacteria in children The patient information leaflet of Ertapenem on pharmaceutical company website Ertapenem, the first of a new group of carbapenems Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms Clinical efficacy of ertapenem for recurrent cystitis caused by multidrug-resistant extended-spectrum βlactamase-producing escherichia coli in female outpatients Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections Efficacy and cost comparison of ertapenem as outpatient parenteral antimicrobial therapy in acute pyelonephritis due to extended-spectrum beta-lactamase-producing enterobacteriaceae Outpatient ertapenem therapy in an ESBL-high-prevalence area: an efficacy, safety, and cost study Mechanisms of ertapenem resistance in Enterobacteriaceae isolates in a tertiary university hospital Quality of outpatient parenteral antimicrobial therapy (OPAT) care from the patient's perspective: a qualitative study Ertapenem resistance in 2 tertiary-care hospitals: Microbiology, epidemiology, and risk factors. Resistencia a ertapenem en 2 instituciones hospitalarias de alto nivel de complejidad: microbiología, epidemiología y factores de riesgo A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure Daily inpatient ertapenem therapy can be an alternative to hospitalization for the treatment of complicated urinary tract infections during the COVID-19 pandemic